Faruqi, LLP also encourages anyone with information regarding uniQure's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.To learn more about the uniQure class action, go to www.faruqilaw.com/QURE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).Follow us for updates on LinkedIn, on X, or on Facebook.Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). ...

SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds NuScale (SMR) Investors of Securities Class Action Deadline on April 20, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In NuScale To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [NuScale] between May 13, 2025 and November 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited (NASDAQ: POM) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose critical information [1] - Specific allegations include involvement in a fraudulent stock promotion scheme, use of offshore accounts for share dumping, and omission of false rumors affecting stock price [1] - The company's public statements were deemed materially misleading and lacked a reasonable basis due to these omissions [1] Group 2: Stock Performance - Pomdoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a decline of roughly $0.12 per share or approximately 24% in a single trading session [1] - This decline followed increased volatility and selling pressure amid broader investor concerns regarding Pomdoctor's financial performance and valuation [1] Group 3: Legal Proceedings - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [1] - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1]

[#StockFraud][#StockMarket]---### ContactsFaruqi & Faruqi, LLP Josh Wilson 877-247-4292 or 212-983- 9330 (Ext. 1310)Social Media Profiles[Faruqi & Faruqi on Facebook][Faruqi & Faruqi on Instagram][Faruqi & Faruqi on LinkedIn][Faruqi & Faruqi on X][Faruqi & Faruqi on YouTube]More News From Faruqi & Faruqi, LLPGet RSS Feed## SMR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds NuScale (SMR) Investors of Securities Class Action Deadline on April 20, 2026NEW YORK--([BUSINESS WIRE])--Faruqi & Faruqi, LLP, a leading ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Lufax Holding Ltd due to allegations of materially misleading business information issued to the public [1] Group 1: Investigation Details - The investigation is prompted by a current report filed by Lufax with the SEC on January 27, 2025, which indicated a proposal to remove Lufax's auditors and a possible delay in the publication of its 2024 annual report [1] - Following this announcement, Lufax's American Depositary Shares (ADSs) experienced a decline of 13.8% on the same day [1] Group 2: Class Action Information - Investors who purchased Lufax securities may be entitled to compensation through a contingency fee arrangement, meaning no out-of-pocket fees or costs are required [1] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [1] Group 3: Rosen Law Firm's Credentials - The firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [1] - Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [1] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Varonis Systems, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Varonis common stock between February 4, 2025, and October 28, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by March 9, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Varonis made materially false and misleading statements regarding its ability to maintain annual recurring revenue (ARR) projections while transitioning customers to a software-as-a-service (SaaS) model [5]. - It is claimed that Varonis was not adequately prepared to convince existing users of the benefits of the SaaS offering, leading to reduced ARR growth potential [5]. - The lawsuit asserts that the misleading statements resulted in investor damages when the true situation was revealed [5].

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Apollo Global Management, Inc. (NYSE: APO) resulting from allegations that Apollo may have issued materially misleading business information to the investing public. So What: If you purchased Apollo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang. ...

New York, New York--(Newsfile Corp. - February 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GSI Technology Inc. (NASDAQ: GSIT) resulting from allegations that GSI Technology may have issued materially misleading business information to the investing public.SO WHAT: If you purchased GSI Technology securities you may be entitled to compensation without payment of any out of pocket fees or costs through a ...

"Company†) (NASDAQ: QURE) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has re...[Back to Newsroom]## Wish your news had this kind of reach?[Sign Up][Learn About Business Wire] SMR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds NuScale (SMR) Investors of Securi ...

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. related to a federal securities class action due to alleged violations of federal securities laws [1] - The complaint alleges that REGENXBIO and its executives made false or misleading statements and failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study [1] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy for MPS I after a case of neoplasm was reported in a participant [1] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [1] - Following the FDA's announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share [1] Group 2 - The deadline for investors to seek the role of lead plaintiff in the class action is April 14, 2026 [1] - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers and former employees [1]